| Name | Title | Contact Details |
|---|
Dren Bio is a San Carlos, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.